(Q36839698)

16 August 2017

1 reference

title

Fosamprenavir calcium plus ritonavir for HIV infection (English)

1 reference

16 August 2017

1 reference

Harrys A Torres

1

1 reference

16 August 2017

Roberto C Arduino

series ordinal

2

1 reference

16 August 2017

publication date

1 June 2007

1 reference

Expert Review of Anti-infective Therapy

16 August 2017

published in

1 reference

16 August 2017

volume

5

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

349-363

1 reference

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Fosamprenavir: drug development for adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

21 January 2018

HIV-protease inhibitors

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Evolution of resistance during first-line treatment with boosted fosamprenavir is associated with baseline mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase n

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Amprenavir Resistance Imparted by the I50V Mutation in HIV-1 Protease Can Be Suppressed by the N88S Mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Interaction between atazanavir and fosamprenavir in the treatment of HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Posaconazole: clinical pharmacology and potential for management of fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Posaconazole: a broad-spectrum triazole antifungal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Voriconazole: a new triazole antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

An update on therapeutic drug monitoring for antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Use of fosamprenavir, a sulfa-containing protease inhibitor, in HIV-infected patients with glucose-6-phosphate dehydrogenase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

Potent cytochrome P450 2C19 genotype–related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.349

21 January 2018

Identifiers

DOI

10.1586/14787210.5.3.349

1 reference

16 August 2017

1 reference